Brief: Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
22/05/2024 13:43
May 22 (Reuters) - Coya Therapeutics Inc COYA.O :
* COYA THERAPEUTICS ANNOUNCES THE COMPLETION OF A CONTROLLED
PHASE
2 STUDY OF LOW DOSE INTERLEUKIN-2 (LD IL-2) IN PATIENTS WITH
ALZHEIMER’S DISEASE
* COYA THERAPEUTICS INC -PHASE 2 TOP LINE DATA ON TRACK TO
BE
REPORTED IN SUMMER OF 2024
Source text for Eikon: ID:nBwbhlq2qa
Further company coverage: COYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)